Silent Pheochromocytoma Is an Underrecognized Clinical Entity: Results From a High-Volume Adrenal Surgery Hospital
Authors' conclusion
SPheo, comprising 14.9% of pheochromocytomas at a high-volume center, is often misdiagnosed due to atypical presentation. Comprehensive biochemical and imaging evaluations, coupled with a high index of suspicion, are critical for accurate diagnosis and timely surgical intervention.
Study context
- Population
- Patients with sporadic pheochromocytoma among 1273 adrenalectomies at a high-volume adrenal surgery hospital, January 2022 to November 2024sporadic pheochromocytoma
- Participants
- 94 patients
- Exposure
- Silent pheochromocytoma vs overt pheochromocytoma
- Silent pheochromocytoma (SPheo)n = 14
- Outcome
- Proportion of sporadic pheochromocytoma meeting SPheo criteria
Methodological detailssingle-centre, high-volume adrenal surgery hospital
- Single-centre
- High-volume adrenal surgery hospital
Main finding
As reported in the abstract
SPheo
14.9%
14
Observational data: associations, not effects.
Further findings
Tumor size · smaller with SPheo
P < 0.01
Biochemical indices (fold change vs upper reference limit) · lower with SPheo
P < 0.0001
- Plasma and urine metanephrines · plasma metanephrines lower with SPheo
- P < 0.0001
- Plasma and urine metanephrines · urine metanephrines lower with SPheo
- P < 0.002
- Diagnosed with MACS at referral (SPheo)
- 42.8% · 6 of 14
Preoperative imaging interpretation at outside institutions (SPheo)
- Adenoma
- 6
- Indeterminate
- 7
- Metastasis
- 1
Original publication
Silent Pheochromocytoma Is an Underrecognized Clinical Entity: Results From a High-Volume Adrenal Surgery Hospital. Endocr Pract. Published 17 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →